2013, Number 1
<< Back Next >>
Biotecnol Apl 2013; 30 (1)
Capacity of viral inactivation of the Melagenina® Plus storing step
Lobaina LI, Noa E, Hernández AM, Dubed M, Navea LM, Pérez JR
Language: Spanish
References: 23
Page: 45-50
PDF size: 181.08 Kb.
ABSTRACT
This work was aimed at validating the viral inactivation property during the storage step of the production process of Melagenina
® Plus, which is a Cuban
biological product for the treatment of vitiligo. The product was challenged at storage with high loads of four
viral models, corresponding to three enveloped and one non-enveloped virus, two of them RNA and the other two DNA viruses: the human immunodeficiency virus type 1 (HIV-1), the bovine viral diarrhea virus (BVDV), the porcine
herpes virus type 1 (PHV-1) and the canine parvovirus (CPV). The viral titer was determined using the Reed-Muench
method based on the viral cytopathic effect, and reduction factors were calculated as the difference of viral loads at
the beginning and the end of the step. Enveloped viruses were inactivated between days 1 to 3, and the enveloped
virus (CPV) was achieved after 21 days. The viral load showed a very highly signifi cant decrease (p ‹ 0.0001), being conditioned to storage temperature (30 ± 5 °C) and ethanol concentration (71 % minimum). The reduction factors achieved on this step (1:5.0 log for HIV-1; 3.5 log for BVDV; 4.24 log for PHV-1 and 5.8 log for CPV) characterized the adequate level of safety of the Melagenina
® Plus production process.
REFERENCES
Miyares C. Melagenina® Plus. Avances Médicos en Cuba. 2000;7(23):50-2.
Miyares CM, inventor; Centro de Histoterapia Placentaria, assignee. Composition for stimulating the synthesis of the melanic pigment and process for obtaining it. United States patent US 6660305. 2003 Dec 9.
Centro para el control estatal y la calidad de los medicamentos. Regulación No. 2/2002. Placenta humana como materia prima farmacéutica. La Habana: Cecmed; 2002.
Chow SS, Craig ME, Jacques CF, Hall B, Catteau J, Munro SC, et al. Correlates of placental infection with cytomegalovirus, parvovirus B19 or human herpes virus 7. J Med Virol. 2006;78(6):747-56.
Indolfi G, Moriondo M, Galli L, Azzari C, Poggi GM, Resti M, et al. Mother-to-infant transmission of multiple blood-borne viral infections from multi-infected mothers. J Med Virol. 2007;79(6):743-7.
Barin F. La sécurité virale des médicaments d’origine biologique. Ann Pharm Fr. 2008;66(3):129-39.
Food and Drug Administration. Current good manufacturing practice for fi nished pharmaceuticals. Subpart E- Control of Components and Drug Product Containers and Closures § 211.80 General requirements (21 CFR 211.80). Rockville MD: Food and Drug Administration. Department of Health and Human Services; 2008.
Noa E, Hernández AM, Ruibal I, Dubed M, Navea L, Lobaina L, et al. Validación de la capacidad de inactivación viral del proceso de producción del extracto placentario loción Melagenina®. Rev Cub Farmacia 2002;36(Suppl 1).
Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; 1996 Feb. CPMP/BWP/269/95. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientifi c_ guideline/2009/09/WC500003684.pdf
Martínez L, Sanz A, Miyares CM, Hollands I, Roque S, Pimienta R, et al. Estudio comparativo del efecto pigmentante de dos extractos de placenta humana (Melagenina I y II). In: La histoterapia placentaria en algunas afecciones dermatológicas. La Habana: Palacio de las Convenciones; 1994.
Johnson VA, Byington RE. Infectivity assay (virus yield assay) In: Aldovani A, Walker BD, editors. Techniques in HIV Research. New York: Stockton Press; 1990. p. 71-6.
Reed LJ, Muench H. A simple method of estimating fi fty percent end point. Am J Hyg 1938;27(3):493-7.
González Y, Salcedo G, García W, Hernández CR, Brito N. Validación de la técnica espectrofotométrica de cuantifi - cación de lípidos totales para el control de la calidad de los extractos de placenta. In: Memorias II Seminario Internacional de Histoterapia Placentaria. La Habana: Centro de Histoterapia Placentaria; 2006.
Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Plasma-Derived Medicinal Products. London: The European Agency for the Evaluation of Medicinal Product, Evaluation of Medicines for Human Use; 2001 Jan. CPMP/BWP/269/95 rev. 3. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientifi c_ guideline/2009/09/WC500003613.pdf
Darling A. Validation of biopharmaceutical purifi cation processes for virus clearance evaluation. Mol Biotechnol. 2002;21(1):57-83.
Tuñón MA, Noa E, Sánchez K, Ruibal IJ, Dubed M, Castañeda F, et al. Desescalado del proceso de producción de Hebertrans® para su validación viral. Biotecnol Apl. 2004;21:229-33.
Azzi A, Maggi F, Zakrzewska K, Menconi MC, Di Pietro N, Salotti V, et al. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purifi cation. Transfusion. 2006;46(7):1162-7.
Suchomel M, Gnant G, Weinlich M, Rotter M. Surgical hand disinfection using alcohol: the effects of alcohol type, mode and duration of application. J Hosp Infect. 2009;71(3):228-33.
Rivera H. Evolución del conocimiento sobre la enfermedad de la diarrea viral bovina y su agente etiológico. Rev Investig Vet Perú. 2008;19(2):93-112.
Ruibal Brunet IJ, Noa Romero E, Rivero Mas AT, Martín García RZ. Inactivación del VDVB (modelo experimental del virus de la hepatitis C) por pH bajo y tratamiento por calor en inmunoglobulinas humanas endovenosa. Sangre (Barc). 1999;44(5):352-6.
Pérez JR, Noa E, Vergel V, Alfaro E, Lovaina L, Sánchez Y, et al. Viral cleaning capacity of the manufacturing process of the EP-100. Avances en Biotecnología Moderna. 2007:CP-43.
Dichtelmûller HO, Germer M, Rudnick DC. A general approach to robustness studies for virus inactivating and partitioning steps used in production of plasma derivatives. Bioprocess Int. 2005;3(Suppl 7): 35-8.
Brorson K. Advances in viral clearance. In:. Shukla AA, Etzel MR, Gadam S, editors. Process scale bioseparations for the biopharmaceutical industry. Boca Raton: CRC Press, Taylor & Francis Group. 2007; p. 449-62.